Pimavanserin:治疗帕金森精神症的新药

摘要

Pimavanserin是选择性5-HT2A反向激动剂,已于2016年4月29日经美国食品药品管理局批准用于治疗帕金森精神症.本文对该药的药理作用、临床应用、药动学研究、用法用量、药物相互作用和不良反应作一综述.%Pimavanserin is a selective serotonin 5-HT2A inverse agonist, it was approved by the Food and Drug Administration (FDA) for treatment of Parkinson's disease psychosis on Apr. 29, 2016. Its pharmacological effects, clinical applications, pharmacokinetics, dosage, drug interactions and adverse reactions were reviewed in this paper.